Content about therapies for cancer

January 26, 2012

Amgen acquiring Micromet for $1.16 billion

Drug maker Amgen is acquiring a Rockville, Md.-based company developing therapies for cancer, the companies said Thursday.

THOUSAND OAKS, Calif. — Drug maker Amgen is acquiring a Rockville, Md.-based company developing therapies for cancer, the companies said Thursday.

Amgen announced plans to buy Micromet for $1.16 billion, or $11 per share. Micromet, originally founded in Germany, is developing blinatumomab, currently in phase-2 trials as a treatment for acute lymphoblastic leukemia and non-Hodgkin's lymphoma. The acquisition also will include the company's research and development center in Munich.

October 6, 2011

Merck KGaA, Ono sign agreement for oral MS, cancer drugs

German drug maker Merck KGaA will collaborate with Japanese drug maker Ono Pharmaceutical to develop oral therapies for cancer and multiple sclerosis, Merck KGaA said.

DARMSTADT, Germany — German drug maker Merck KGaA will collaborate with Japanese drug maker Ono Pharmaceutical to develop oral therapies for cancer and multiple sclerosis, Merck KGaA said.